Mizuho Maintains Buy on Insmed, Raises Price Target to $36
Portfolio Pulse from Benzinga Newsdesk
Mizuho analyst Graig Suvannavejh maintains a Buy rating on Insmed (NASDAQ:INSM) and raises the price target from $35 to $36.
May 13, 2024 | 1:49 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Mizuho analyst Graig Suvannavejh reaffirmed a Buy rating on Insmed and increased the price target from $35 to $36, indicating a positive outlook on the company's stock.
Analyst ratings and price target adjustments are significant indicators for stock performance in the short term. The increase in price target by Mizuho suggests a strong confidence in Insmed's future performance, likely leading to positive investor sentiment and potentially an increase in stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100